Celltrion

Celltrion takes over French health care firm Gifrer The Korea Times04:02France

Celltrion’s Zymfentra sees 185% surge in US prescriptions The Korea Herald03:36

Celltrion’s profit doubles as biosimilar demand drives record revenue The Korea Times04:08Pharma Biotechnology Biotech

Celltrion files Herceptin biosimilar SC formulation with EMA Korea Biomedical Review09:03European Medicines Agency

Celltrion buys France’s Gifrer to tap expanding biosimilar substitution market Korea Biomedical Review05:56France Biotechnology

Celltrion highlights new CT-P13 SC data at Ddw 2026, reinforcing IBD treatment potential Korea Biomedical Review05:34Inflammatory Bowel Disease

Celltrion launches Avtozma in Japan, entering tocilizumab market as first mover Korea Biomedical Review05:14Japan Tocilizumab

Celltrion’s Q1 operating profit more than doubles on biosimilar growth Korea Biomedical Review03:35Inflammatory Bowel Disease

Celltrion acquires entire stake in French health care company Gifrer Yonhap News Agency12:10France Biotechnology South Korea

Celltrion posts record first-quarter results Miami Herald16:04Seoul

Latest News

In the last 8 hours

Analysts grow more bullish on Celltrion as margin expansion gains traction Korea Biomedical Review01:08

In the last 7 days

Celltrion acquires entire stake in French health care company Gifrer Yonhap News Agency12:10 12-May-26

Celltrion buys France’s Gifrer to tap expanding biosimilar substitution market Korea Biomedical Review05:56 12-May-26

Celltrion takes over French health care firm Gifrer The Korea Times04:02 12-May-26

Gifrer Acquisition To Boost Celltrion’s French Reach, Portfolio Scrip Pharma Intelligence03:48 12-May-26

Celltrion buys France’s Gifrer to expand beyond biosimilars The Korea Herald03:22 12-May-26

Spotlight On: Rituxan® (rituximab) / Truxima® (rituximab-abbs) / Ruxience® (rituximab-pvvr) / Riabni™ (rituximab-arrx)… JD Supra19:46 11-May-26

Spotlight On: Biosimilar Litigations - May 2026 JD Supra19:16 11-May-26

Celltrion’s Zymfentra sees 185% surge in US prescriptions The Korea Herald03:36 8-May-26

Celltrion highlights new CT-P13 SC data at DDW 2026, reinforcing IBD treatment potential Korea Biomedical Review05:34 7-May-26

In the last month

Celltrion posts record first-quarter results Miami Herald16:04 6-May-26

Celltrion Q1 Net Income Rises RTT News05:32 6-May-26

Celltrion’s profit doubles as biosimilar demand drives record revenue The Korea Times04:08 6-May-26

Celltrion’s Q1 operating profit more than doubles on biosimilar growth Korea Biomedical Review03:35 6-May-26

Celltrion posts record Q1 earnings on strong biosimilar sales The Korea Herald03:26 6-May-26

Celltrion Q1 net income up over 3-fold on high-margin products Yonhap News Agency01:47 6-May-26

Celltrion files Herceptin biosimilar SC formulation with EMA Korea Biomedical Review09:03 30-Apr-26

Celltrion enters Japanese market for arthritis treatments with new biosimilar The Korea Times07:27 28-Apr-26

Celltrion launches Avtozma in Japan, entering tocilizumab market as first mover Korea Biomedical Review05:14 28-Apr-26

Celltrion begins dosing for 3 ADC cancer candidates Korea Biomedical Review06:30 23-Apr-26

Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive… PR Newswire (Press Release)13:07 21-Apr-26

Celltrion obtains Japanese approval for Steqeyma IV formulation Korea Biomedical Review09:09 21-Apr-26

Spotlight On: Herceptin® (trastuzumab) / Ogivri® (trastuzumab-dkst) / Herzuma® (trastuzumab-pkrb) / Ontruzant®… JD Supra16:45 17-Apr-26

Spotlight On: Biosimilar Litigations - April 2026 JD Supra21:23 16-Apr-26

Spotlight On: Rituxan® (rituximab) / Truxima® (rituximab-abbs) / Ruxience® (rituximab-pvvr) / Riabni™ (rituximab-arrx)… JD Supra20:11 16-Apr-26

Celltrion gains ground in Europe as prescriptions rise across portfolio Korea Biomedical Review05:22 16-Apr-26

Celltrion becomes only Korean biotech firm in S&P Global's top 1% ESG companies Korea Biomedical Review05:22 15-Apr-26

Celltrion named Top 1% in S&P Global ESG ranking The Korea Herald03:18 15-Apr-26

Celltrion completes largest-ever share cancellation in Korean biotech Korea Biomedical Review05:54 14-Apr-26

view more headlines

14 May 01:08

About our Celltrion news

Latest news on Celltrion, a biopharmaceutical company headquartered in Incheon, South Korea.

Publication filters

Sorry, no headlines or news topics were found. Please try different keywords.